Navigation Links
The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market
Date:5/20/2009

Commercial Potential of Market is Reflected in Burgeoning Pipeline of More than 400 Drugs in Development, According to a New Report from Decision Resources

WALTHAM, Mass., May 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of more than 20 novel antidiabetic drugs over the next 10 years will drive the type 2 diabetes market to increase by $12.5 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Type 2 Diabetes finds that both novel and existing DPP-IV inhibitors and GLP-1 analogues - such as Merck's Januvia, Bristol-Myers Squibb/AstraZeneca's Onglyza and Amylin/Eli Lilly/Alkermes' Byetta LAR - hold the greatest promise for type 2 diabetes because these drug classes improve upon key areas of safety and efficacy. DPP-IV inhibitors have a very low risk of hypoglycemia and an excellent tolerability profile, making them suitable for widespread use. GLP-1 analogues, which combine superior glucose-lowering and weight loss capabilities compared with other drug classes, are particularly useful treatments for the significant proportion of type 2 diabetics who are obese.

"The commercial potential for drugs with demonstrated disease-modifying capabilities and long-term efficacy is reflected in the burgeoning pipeline for type 2 diabetes, which currently has more than 400 drugs in active development," said Decision Resources Analyst Christine Helliwell, Ph.D. "However, with a greater regulatory burden in the United States and an increasingly crowded market, the barriers for success are higher than ever before."

The report also finds that generic competition will weaken the market share of the PPAR-gamma agonists--Takeda's Actos and GlaxoSmithKline's Avandia--reducing sales of these agents by more than 50 percent over the 2008 to 2018 study period. The PPAR-gamma agonists, along with metformin (Bristol-Myers Squibb/Merck Sorono's Glucophage/Glucophage XR, Biovail/Depomed's Glumetza, Watson's Fortamet, generics) and the sulfonylureas, both of which are already generically available, are the most commonly prescribed first-, second-, and third-line oral therapies. Generic availability of all three drug classes will provide formidable competition for new, more-expensive drugs in the market.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

    Decision Resources               Decision Resources, Inc.
    Christopher Comfort              Elizabeth Marshall
    781-296-2597                     781-296-2563
    ccomfort@dresources.com          emarshall@dresources.com

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. American College of Physicians Chooses iPublishCentral to Launch its e-Book Strategy
2. USMLE Galaxy, LLC Launches Live and Cost Effective USMLE Review Courses and Practice Sessions Right on Your Desktop through its Subsidiary CcsWorkshop.com
3. Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease
4. American College of Physicians Chooses iPublishCentral to Launch its e-Book Strategy
5. Gold Star Resources Corp. Launches Humanitarian Society to Aid Liberian People
6. Photos: Will Ferrell Sunscreen to Launch Just in Time for Summer
7. Booty Camp(R) Potty Training Program as Featured in People Magazine is Launched on DVD
8. IBD Patient Launches iPhone Application to Help Doctors Treat Crohns and Ulcerative Colitis
9. Photos: USANA Launches National Rev3 Geocaching Challenge
10. ACORN CRO Launches STAR (Site Tracking and Recruitment)
11. StreetWise HSA(SM) Launched Nationally: First Low-Cost, Customizable Platform for Employee HSA Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 , ... ... fact, there are a number of illnesses that are unclear as to whether or ... of their heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look ...
(Date:4/28/2017)... ... 2017 , ... Getting enough sleep affects much more than energy – it also has mental ... sleep can compromise motor reaction time, which can increase the risk of having a car ... following tips from the NSF to help you sleep better and feel better:, ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... National Harbor, Md. (PRWEB) , ... April 28, ... ... Urgent Care Association of America (UCAOA) and College of Urgent Care Medicine will ... Momentum 2017 workshops, sessions and speakers will help those in the industry adapt ...
(Date:4/28/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, has published a new post that ... Yisrayl says with so many titles and names for the Creator, it’s hard for many ... Scripture, backed with a lot of research, the truth is undeniable. , “If you ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
Breaking Medicine Technology: